Background. Prospective database studies can provide useful information regarding 'real-world' outcomes and drug efficacy.
Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease with increasing prevalence in Poland [1] . The course of the disease and its associated rate of disability progression are highly unpredictable and constitute the most common primary neurological cause of disability in young adults [2] . The continued development of diagnostic criteria and increased awareness of typical clinical features have allowed shortening of the diagnosis delay and an earlier initiation of treatment [3] . An analysis of the disease onset symptoms and initial relapse rate can help to estimate the most probable course of the disease, with specification as to its aggressiveness [4] . However, the question as to which drug should be chosen for the treatment is still unresolved. The country-wide standardised inclusion and reassessment criteria allowed us to make joint analyses of patients from different centres at a time when only injectable disease modifying treatments (DMT) were available in Poland. First line injectable treatment options included different formulations of interferon beta (INT-β): subcutaneous IFN-β-1b, IFN-β-1a and intramuscular IFN-β-1a or subcutaneous glatiramer acetate (GA). These are well established safety immunomodulatory drugs with all-over efficacy defined in randomised trials at about 30% [5] [6] [7] [8] . This includes a moderate influence on lowering the relapse rate and on the clinical and radiological progression of disability. At a time when there are a growing number of newly available treatment options, it is still important to analyse previously used algorithms, either to reestablish them or to ensure correct treatment decisions [9] .
Material and methods

Patients
The research design was a multi-centre prospective database study. Four medical centres (Bydgoszcz, Szczecin, Białystok, Zabrze) providing immunomodulatory treatment of MS within the nationally funded treatment programme participated in the research.
Inclusion criteria: adult (over 18 years old) patients with relapsing-remitting (RR) MS who started an injectable DMT between January 2008 and June 2013 were included in this study. The follow-up continued to July 2014. All participants met the 2005 McDonald criteria for MS and had either two relapses or one relapse and a chronologically (three months) separate gadolinium enhancing lesion on magnetic resonance imaging (MRI), within the immediate two year period preceding the start of DMT [3] . We included either patients with a newly confirmed diagnosis or untreated for at least the last six months with a new exacerbation and an Expanded Disability Status Score (EDSS) of up to 4.5. During the time of data collection (between 2008 and 2011), the treatment duration regime in Poland was limited to three years. Some active patients could be recruited several times, always after a new instance of disease exacerbation. Treatment selection for IFN β or GA was based on national eligibility criteria. Patients with Clinical Isolated Syndrome (CIS) or progressive forms of MS were not eligible for this study.
Ethics
The work described in this article has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; we have followed uniform requirements for manuscripts submitted to biomedical journals.
Cohorts
The time of treatment initiation and a follow-up period of a minimum of two years allowed us to make a comparative observation of two cohorts. Cohort A comprised patients included from January 2008 up to May 2012, eligible after at least two relapses during the last 24 months before qualification to the treatment. Cohort B comprised patients included from June 2012, eligible after at least one relapse during the last 12 months before qualification to the treatment.
Method
Patient data was collected in an electronic case report form. Clinical and demographic parameters were analysed. The disease activity was determined by the annualised relapse rate (ARR) defined as: MS-related hospitalisation, MS-related Emergency Room visit or MS-related outpatient visit with corticosteroid prescription ± 7 days within one year. EDSS scoring was performed every three months during the treatment by trained staff [10] . Clinical neurological progression was defined as a change of EDSS score of more than 1.0 that was persistent for longer than three months despite a lack of relapse. Magnetic resonance imaging (MRI) was performed at the beginning and after each year of treatment, and was focused on detecting new emerging T2 lesions or/and a gadolinium (GD) enhancing lesion.
Outcomes were defined on the basis of the RIO score: Optimal clinical response is described as no relapses, no progression in disability (defined as stable EDSS or with a change of less than 1.0) within a year. Optimal radiological response is defined as no changes in NMR (no gadolinium enhancing lesion and less than two T2 lesions). The definition is similar to a RIO score of zero. Suboptimal clinical response is described as one or more relapse and/or progression in disability (defined as increase of EDSS ≥ 1.0) and/or suboptimal radiological response, defined as > 1 active gadolinium enhancing lesion and/or > 2 T2 lesions in a year. This definition is similar to a RIO score of 1 or more [11] .
Statistics
Statistical analysis was performed using R (The R Project for Statistical Computing)-R version 3.4.2. In descriptive statistics, the following tests were used: Fisher's exact test to establish differences in proportions, T-test to establish differences in quantitative data (for normally distributed data), Wilcoxon test to establish differences in quantitative data (for non-normally distributed data), Anderson-Darling test to establish the normality of given quantitative data. In order to determine the influence of main neurological rates (symptoms on MS onset, EDSS) on drugs suboptimal response, univariable logistic regressions were performed.
Results
Two hundred and ninety seven MS patients met the inclusion criteria. The female to male ratio was 2.3:1. The average age of the patients was 35.37 ± 9.92 years (range 18-64 years), and the patients showed mild disability characterised by a mean baseline EDSS of 1.95 ± 1.05. The average treatment delay was 4.12 ± 4.81 years (range 0-24 years). The two studied cohorts were comparable without significant differences on baseline, except for the fact that the more recently included patients (Cohort B) were older, more disabled and more active in their disease course (p 0.01). In both cohorts, the proportion between the newly diagnosed-naïve and previously treated patients was similar (Tab. 1).
Clinical outcome with injectable DMT Over 85% of patients were under INF β treatment with a mean follow-up time of 2.3 ± 1.3 years (range 1-5). After three years of treatment, no relapses and stable EDSS was observed in 91 patients (85%) which constitutes about one third of the baseline population. The patient loss in follow-up was mainly due to a treatment time limited to three years, established by the nationally funded treatment programme. The evidence of suboptimal treatment response defined as evidence of clinical and/or radiological activity, was stable in the follow up-period, within the range of 15-18%. The reason for stopping or switching the initial DMT therapy was mainly driven by the instability of the clinical course. The mean EDSS score was stable over three years of treatment at about 2.0; we also observed a significant and stable reduction of ARR and GD enhancement p < 0.01 (Tab. 2).
Main predictors of suboptimal response to injectable DMT in three years follow-up
Suboptimal clinical response, defined as a RIO score ≥ 1, was further analysed in two separate categories: clinical and radiological response. In univariable logistic regression, the factors predicting worse response to injectable DMTs were comparable in the whole three years of the follow-up period. The main predictor of inefficacy in the first and second years of treatment was the baseline clinical status. With an increase in disability defined as baseline EDSS ≥ 3, the risk of treatment failure increased to over seven times (in the second year radiological analysis), similar to over two times with baseline symptomatic hemiparesis, which in fact influences the EDSS 
Discussion
Open compartmental studies concerning first-line RRMS treatment have shown a significant reduction of disease activity. In the first two years of INF B treatment, the ongoing disease activity has been reported as between 16% and 29% [12] [13] [14] [15] [16] . Freedom from disease activity has become a widely proposed system of optimal clinical outcomes analysis based on relapse rate, EDSS and radiological signs of new active lesions. The often used RIO score can be translated to NEDA showing an optimal disease control in a similar way [16] [17] [18] . In this multi-centre prospective database study, we showed a high efficacy of injectable first-line DMTs. This was achieved by a good clinical response in lowering the BL rate of ARR from 1.3 to 0.13 (after one and two and three years of treatment). EDSS stabilization, together with the reduction of radiological progression, resulted in good disease control in over 80% of patients.
Some other studies, in so far as our results, show high efficacy of first-line injectable medications in the treatment of RRMS patients [18] [19] [20] [21] [22] [23] . In the study by Sorenson et al., based on the Danish Nationwide Database containing health records from RRMS patients, there was no clear difference in the efficacy of immunomodulatory treatment with injectable DMTs [22, [24] [25] .
We based the comparison of the optimal and suboptimal treatment responses on the RIO score. To analyse the predictors for suboptimal response, we concentrated mainly on baseline variables that could lead to treatment failure. Baseline EDSS ≥ 3 or hemiparesis as the initial MS manifestation increases such a risk more than two times. A similar conclusion without any specific cut-off was described in an 18 year-long observational cohort study of treatment-naïve patients from Canada [19] . Also in other reports, high EDSS score has been considered to be the main factor predicting interruption of therapy, which in fact is similar to a suboptimal treatment response [26] [27] . Due to the therapy outcome optimisation, it is recommended attention be paid to more active/progressive patients at diagnosis [4] . Those patients with higher levels of disability in the early relapsing-remitting course of the disease should be considered as highly active, with an indication for therapeutic decisions other than first line DMTs [9] . The same is true for relapse active patients before the treatment, as relapses are the clinical manifestation of inflammation. In our cohort, the risk of being suboptimal responders at three years was more than three times higher for relapse active patients one year before treatment.
Another important aspect that we took into consideration was treatment efficacy estimation by early and late therapy initiation. We could compare the outcomes form treatment--naive and retreated patients. This observation was possible because of country-specific regulation on the time of data collection. According to the previously used (from 2008 to 2012) guidance, the nationally funded treatment programme was limited to three years. Some active patients could be recruited several times, always after a new exacerbation of the disease. The average treatment delay in our study was four years. Only 28% (85) of patients were treated within > 12 months after diagnosis as treatment-naïve. Nearly 27% started the treatment later than five years, and 11% later than 10 years, after diagnosis. Despite not proven worsening of efficacy, treatment delay in our study was twice as long as that observed in a comparable time frame in Spain [28] . Taking into consideration the differences between treatment-naïve and retreated patients, we could only confirm a worse outcome in patients with profound clinical disability on treatment initiation, without differences between these two groups.
In previous Polish analysis, immunomodulatory drugs were used in only 24% of patients: mainly INF β (81%) and GA (13%) [29] . This time, the analysis showed a similar proportion and consistent INF β dominance, in contrast to other countries [19] . In a similar observation period in the US, nearly 40% of newly-diagnosed MS patients were on treatment [30] . This shows that the problem with treatment initiation is not only related to country-specific regulations or budget, but also to patients' and physicians' beliefs in its efficacy and safety.
In a long term observation of injectable DMTs, the stop/ switch rates were mainly dependent on treatment duration, with intolerance as the primary reason for stopping, followed by inefficacy [19, [31] [32] [33] [34] [35] [36] [37] . Persistence in specific therapy indirectly describes the treatment efficacy. In our study, the efficacy was over 80% but the persistence was influenced rather by no other treatment options at that time.
Our study had some methodological shortcomings due to its multi-centre nature. Follow-up MRI scans were performed and analysed in different locations, albeit under one assessment protocol [38] . The same is true for EDSS scoring. An average treatment delay estimated as almost four years after MS diagnosis is another limitation of our study. However, this reflected the fact that country-specific qualification procedures led to late initiation of the treatment, which is inconsistent with common standards. We could determine the baseline predictive correlations only in univariate logistic regression analysis.
Many novel MS medications have been registered recently [39] and integrated to an improved MS treatment programme in Poland. Confronting the previously used algorithms with well-established outcomes control (RIO score) that we have used so far provides the insight that injectable DMTs are effective in RRMS patients (causing lowering of ARR and disease activity reflected in MRI) with limitation to less active and less clinically well patients. Our findings confirm that a careful baseline variables assessment can be helpful in predicting treatment response in injectable first-line drugs.
Conclusions
Patients with greater disability (EDSS ≥ 3) at treatment initiation or hemiparesis as the initial symptom were more likely to fail at the second year of treatment. A high relapse rate one year prior to treatment adversely influences the treatment success at three years. Our findings confirm that first-line injectable drugs should not be chosen for treatment initiation in motoric disabled patients with a high grade of clinical activity. These drugs are effective in less active MS--RR patients.
